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SCIENTIFIC EDITORIAL
REACH: from registry to harmonization
REACH : du registre jusqu’à l’harmonisation
J. Ferrières*
Service de cardiologie B, Centre hospitalier universitaire Rangueil, Toulouse.
From 1980 to 2004, mortality due to cardiovascular disease
has fallen by 52% in France [1]. This reduction is a major
cause of satisfaction for the cardiological community. The
improvement in prognosis is due to the management of car-
diovascular disease and its risk factors. This large fall of
cardiovascular mortality masks an important increase in the
prevalence and costs generated by this chronic disease.
Population registries are necessary to detect the best
means of improving management of atherothombosis. Clini-
cal trials will always provide the ultimate proof of the effi-
cacy of a treatment in a selected sample. Nevertheless, the
most recent clinical trials show that this remarkable mana-
gement of cardiovascular disease does not necessarily
reflect the real situation in the field.
The French REACH registry presented in this issue by
Sabouret et al. [2] is an observational study. The one-year
follow-up results for this cohort have been presented at
international level [3-5] and are discussed for France in this
article [2]. The REACH registry is not above criticism, as
bias may be introduced during selection of the doctors
taking part in the study and patients enrolled in this regis-
try. This registry should consequently be considered to
provide an optimistic view of the real situation. The outs-
tanding finding of this study is the major cardiovascular
event rate which increases from 11.7% at one year for a sin-
gle atherothrombotic lesion to 22.3% at one year for several
atherothrombotic localizations. It should be noted that the
REACH registry includes patients with established athero-
thrombotic disease whereas a high prevalence of asympto-
matic lesions is known to exist in patients presenting
disease in a given territory [6,7].
What lessons may be learned from the REACH study? The
REACH study is first of all a superb example of the evaluation
of professional practices. This evaluation may be made at a
cross-sectional or longitudinal level. A cross-sectional
approach is used to assess the appropriateness of prescrip-
tions with recommendations whereas cohort studies evaluate
the impact of management on cardiovascular events. The
registry REACH data underline the need for a harmonization
of practices in the treatment of a single disease, athero-
thombosis. Screening and management must be harmonized
in the face of a common physiopathology. The community of
doctors and researchers concerned by atherothombosis has
not yet made any final recommendations about the harmoni-
zation of screening after the detection of a first cardiovascu-
lar event in a given territory. Should all atherothrombotic
patients with peripheral arterial occlusive disease be scree-
ned by measuring the ankle-brachial pressure index [8]? Is it
necessary to screen for carotid arterial disease in all patients
after an acute coronary syndrome [9]? Should a test for
ischemia or a coronary CT-scan be conducted in all patients
with peripheral arterial occlusive disease or another athe-
rothrombotic lesion [10,11]? The data of many studies inclu-
ding the REACH registry seem to suggest that it is necessary
to screen for disease in other territories once a first sympto-
matic localization is detected. From the point of view of the-
rapy, the increasing harmonization of practices seems easier
to achieve now that numerous studies have brought together
cardiologists, neurologists and vascular specialists. This must
not be restricted to university hospital collaboration and
doctors working in the wider community must also benefit
from these advances. Registries must therefore be multiplied
as they provide an educational link between researchers and
doctors practicing daily in the field of cardiovascular medi-
cine. These registries make it possible to assess professional
practices and measure the gap between the results of clini-
cal trials and a real life setting. In all events, the REACH
registry has achieved its main goal of making the cardiovas-
cular community aware of the need for common global
management of atherothrombotic disease.
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